Streptokinase Articles
ThromboGenics transfers technology to Bharat
10 September 2007
ThromboGenics and Bharat sign THR licensing deal
11 December 2006
Actilyse gets stroke indication in EU
3 February 2003
Angiomax reduces death in HERO-2 trial
3 September 2001
India's Shanta to launch new products
31 August 2001
More drugs for UK ambulance paramedics
22 November 2000
FDA backs Lovenox for seventh indication
22 November 2000
The Medicines Co Start Hirulog Phase III Trial
8 December 1998
Vascular Thera Completes $22.44 Mill Placement
17 July 1998
ECASS II: More Bad News For Thrombolysis In Stroke
16 July 1998
Argatroban In Acute Myocardial Infarction
8 April 1998
Saruplase Set For Spring 1998 Launch
25 November 1997
ReoPro As Adjunct To Thrombolysis; TIMI 14
20 November 1997
Adenosine + Thrombolysis Cuts Infarcts
18 November 1997
New Studies At European Cardiology Meeting
15 September 1997
Texas Files NDA For Novastan
9 July 1997
Ph II Data With Texas' Novastan In Acute MI
7 April 1997
GUSTO III: Activase Fends Off Retevase Challenge
20 March 1997
Product News In 1996 Dominated By CNS
23 December 1996
First Launch Of Reteplase Follows EU/US Approvals
11 November 1996
First Phase II Data With Argatroban In AMI
28 October 1996
Thrombolysis In Stroke; Bad News Follows Good
12 August 1996
Reteplase Backed By FDA Panel
13 May 1996
HERO Study Finds Hirulog Benefit In Heart Attack
1 April 1996
INJECT Substudy Shows Reteplase Benefit
26 February 1996
Activase Shows Promise In Stroke; Filing Set For 1996?
8 January 1996
TIMI 9b; Hirudin Shows No Advantage Over Heparin
4 December 1995
CytRx Told Not To Push On With RheothRx Trial
18 September 1995
OASIS Pilot Results Suggest Hirudin Benefit
11 September 1995
Reteplase Holds Promise For Acute MI Patients
14 August 1995
Pharmacoeconomic Data From GUSTO Supports tPA
5 June 1995
Introducing Biopharma Drugs Into Europe
17 April 1995
NEW YORK STOCK COMMENT
10 April 1995
Accelerated Activase Regimen Approved
10 April 1995
Streptokinase Trial Halted
16 January 1995
TLC's Liposomal Prostaglandin
19 December 1994
FDA Broadens Genentech Probe
14 November 1994
GUSTO IIa Halted Amid Safety Concerns
7 November 1994
FDA PANEL BACKS ACCELERATED T-PA
20 June 1994
UNCLOGGING THE ISSUES IN THROMBOLYSIS
13 June 1994
WELLCOME'S RHEOTHRx CUTS INFARCT SIZE
11 April 1994
CUBA CLAIMS STRONG DRUG INDUSTRY GROWTH
24 January 1994
RESEARCH AND INVESTMENT IN CARDIOLOGY
20 December 1993
NEW DATA ON ACTIVASE FROM GUSTO TRIAL
29 November 1993
THROMBOLYSIS DEBATE RESTARTS WITH GUSTO
13 September 1993
NEW YORK STOCK COMMENT
17 May 1993
T-PA BACKED BY GUSTO STUDY RESULTS
10 May 1993
GUSTO STUDY ANNOUNCEMENT
26 April 1993
BALANCING PUBLIC AND SHAREHOLDER INTERESTS
5 April 1993
CLINTON VICTORY GOOD FOR SOME PHARMA COS
9 November 1992
GENENTECH REBUFFS ISIS-3 AND AWAITS GUSTO
6 April 1992
GENENTECH REBUFFS ISIS-3 AND AWAITS GUSTO
6 April 1992
EFPIA CHALLENGES EC DRAFT ON DRUG PRICING
16 March 1992
Showing 1-57 of 57 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
